State of Wyoming Purchases New Position in Gilead Sciences, Inc. (NASDAQ:GILD)

State of Wyoming bought a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 6,384 shares of the biopharmaceutical company's stock, valued at approximately $590,000.

Other hedge funds have also added to or reduced their stakes in the company. HHM Wealth Advisors LLC grew its position in Gilead Sciences by 118.5% in the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 154 shares in the last quarter. YANKCOM Partnership bought a new position in shares of Gilead Sciences in the 4th quarter valued at about $28,000. Crews Bank & Trust bought a new position in shares of Gilead Sciences in the 4th quarter valued at about $31,000. Stephens Consulting LLC grew its position in shares of Gilead Sciences by 325.0% in the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock valued at $31,000 after acquiring an additional 260 shares during the period. Finally, Newbridge Financial Services Group Inc. bought a new position in shares of Gilead Sciences in the 4th quarter valued at about $33,000. Institutional investors own 83.67% of the company's stock.

Gilead Sciences Stock Performance

Gilead Sciences stock traded down $1.39 during midday trading on Wednesday, hitting $107.72. The company's stock had a trading volume of 7,958,565 shares, compared to its average volume of 7,713,999. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $119.96. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The company has a 50-day moving average price of $105.44 and a two-hundred day moving average price of $100.07. The company has a market cap of $134.00 billion, a price-to-earnings ratio of 291.14, a PEG ratio of 0.71 and a beta of 0.26.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, beating the consensus estimate of $1.77 by $0.04. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The firm had revenue of $6.67 billion for the quarter, compared to analyst estimates of $6.77 billion. During the same period last year, the firm earned ($1.32) EPS. The business's quarterly revenue was down .3% compared to the same quarter last year. As a group, sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be issued a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.93%. The ex-dividend date of this dividend is Friday, June 13th. Gilead Sciences's dividend payout ratio is currently 66.53%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 17,929 shares of the firm's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $118.17, for a total value of $2,118,669.93. Following the transaction, the chief financial officer now directly owns 169,061 shares of the company's stock, valued at $19,977,938.37. This trade represents a 9.59% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold a total of 22,929 shares of company stock valued at $2,634,220 in the last ninety days. 0.27% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research analysts have recently commented on GILD shares. Wells Fargo & Company lifted their price objective on shares of Gilead Sciences from $120.00 to $140.00 and gave the company an "overweight" rating in a research report on Wednesday, March 5th. The Goldman Sachs Group lifted their price objective on shares of Gilead Sciences from $85.00 to $96.00 and gave the company a "neutral" rating in a research report on Wednesday, February 12th. Bank of America lifted their price objective on shares of Gilead Sciences from $116.00 to $126.00 and gave the company a "buy" rating in a research report on Wednesday, March 5th. Cantor Fitzgerald started coverage on shares of Gilead Sciences in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 price objective for the company. Finally, Oppenheimer cut their target price on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a research note on Friday, April 25th. Nine analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $110.55.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.